Figure 3.

Functional targeting of the endocytic collagen receptor, uPARAP/Endo180, protects against bone destruction in an osteosarcoma mouse model (A) MicroCT scans of tumor and contralateral non-tumor bearing bones from mice treated with either an anti-uPARAP/Endo180 monoclonal antibody (blocking mAb) or an irrelevant control mAb. White arrow indicates the site of sarcoma cell inoculation. (B) Quantification of (A). The blocking mAb leads to a pronounced protection against tumor-dependent bone destruction. ** p = 0.002, Welch’s t-test. Reproduced with permission from Engelholm et al., Journal of Pathology; published by John Wiley and Sons, 2016 [70].